Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas R Miller

Showing results (51-60 of 75) with videos related to

Pageof 8
Sort By:
Assay and Drug Development Technologies|July 3, 2008
A robust and high-capacity [(35)S]GTPgammaS binding assay for determining antagonist and inverse agonist pharmacological parameters of histamine H(3) receptor ligandsThomas R Miller, John L Baranowski, Brian R Estvander, et al.
Journal of Medicinal Chemistry|July 11, 2009
Design of a new histamine H3 receptor antagonist chemotype: (3aR,6aR)-5-alkyl-1-aryl-octahydropyrrolo[3,4-b]pyrroles, synthesis, and structure-activity relationshipsChen Zhao, Minghua Sun, Youssef L Bennani, et al.
Life Sciences|May 30, 2006
Evidence for tolerance following repeated dosing in rats with ciproxifan, but not with A-304121Jia Bao Pan, Betty B Yao, Thomas R Miller, et al.
Bioorganic & Medicinal Chemistry Letters|July 13, 2002
Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1Ramin Faghih, Wesley Dwight, Robert Gentles, et al.
Bioorganic & Medicinal Chemistry Letters|February 23, 2010
Rigidified 2-aminopyrimidines as histamine H4 receptor antagonists: effects of substitution about the rigidifying ringJohn R Koenig, Huaqing Liu, Irene Drizin, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 28, 2003
Two novel and selective nonimidazole histamine H3 receptor antagonists A-304121 and A-317920: I. In vitro pharmacological effectsTimothy A Esbenshade, Kathleen M Krueger, Thomas R Miller, et al.
Bioorganic & Medicinal Chemistry Letters|July 13, 2002
Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifsRamin Faghih, Wesley Dwight, Larry Black, et al.
Basic & Clinical Pharmacology & Toxicology|September 28, 2004
In vitro optimization of structure activity relationships of analogues of A-331440 combining radioligand receptor binding assays and micronucleus assays of potential antiobesity histamine H3 receptor antagonistsArthur A Hancock, Marilyn S Diehl, Ramin Faghih, et al.
Medical Care|May 15, 2007
Hospital episodes and physician visits: the concordance between self-reports and medicare claimsFredric D Wolinsky, Thomas R Miller, Hyonggin An, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 15, 2007
An 80-amino acid deletion in the third intracellular loop of a naturally occurring human histamine H3 isoform confers pharmacological differences and constitutive activityGerold Bongers, Kathleen M Krueger, Thomas R Miller, et al.
Pageof 8

Showing results (51-60 of 75) with videos related to

Sort By:
Pageof 8
Assay and Drug Development Technologies|July 3, 2008
A robust and high-capacity [(35)S]GTPgammaS binding assay for determining antagonist and inverse agonist pharmacological parameters of histamine H(3) receptor ligandsThomas R Miller, John L Baranowski, Brian R Estvander, et al.
Journal of Medicinal Chemistry|July 11, 2009
Design of a new histamine H3 receptor antagonist chemotype: (3aR,6aR)-5-alkyl-1-aryl-octahydropyrrolo[3,4-b]pyrroles, synthesis, and structure-activity relationshipsChen Zhao, Minghua Sun, Youssef L Bennani, et al.
Life Sciences|May 30, 2006
Evidence for tolerance following repeated dosing in rats with ciproxifan, but not with A-304121Jia Bao Pan, Betty B Yao, Thomas R Miller, et al.
Bioorganic & Medicinal Chemistry Letters|July 13, 2002
Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1Ramin Faghih, Wesley Dwight, Robert Gentles, et al.
Bioorganic & Medicinal Chemistry Letters|February 23, 2010
Rigidified 2-aminopyrimidines as histamine H4 receptor antagonists: effects of substitution about the rigidifying ringJohn R Koenig, Huaqing Liu, Irene Drizin, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 28, 2003
Two novel and selective nonimidazole histamine H3 receptor antagonists A-304121 and A-317920: I. In vitro pharmacological effectsTimothy A Esbenshade, Kathleen M Krueger, Thomas R Miller, et al.
Bioorganic & Medicinal Chemistry Letters|July 13, 2002
Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifsRamin Faghih, Wesley Dwight, Larry Black, et al.
Basic & Clinical Pharmacology & Toxicology|September 28, 2004
In vitro optimization of structure activity relationships of analogues of A-331440 combining radioligand receptor binding assays and micronucleus assays of potential antiobesity histamine H3 receptor antagonistsArthur A Hancock, Marilyn S Diehl, Ramin Faghih, et al.
Medical Care|May 15, 2007
Hospital episodes and physician visits: the concordance between self-reports and medicare claimsFredric D Wolinsky, Thomas R Miller, Hyonggin An, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 15, 2007
An 80-amino acid deletion in the third intracellular loop of a naturally occurring human histamine H3 isoform confers pharmacological differences and constitutive activityGerold Bongers, Kathleen M Krueger, Thomas R Miller, et al.
Pageof 8